Caplin Point Q1FY27: PAT +18.8% YoY to ₹179 Cr, EBITDA margin expands, tax caps NPM
PAT +18.79% YoY · revenue +19.62% · margins expanding · inline vs street
₹610.36 Cr
+19.62% YoY
₹179.09 Cr
+18.79% YoY
27.81%
-0.5pp YoY
₹23.27
Caplin Point's consolidated Q1 FY27 revenue from operations came in at ₹610.4 Cr, up 19.6% YoY (₹510.2 Cr) and 1.7% QoQ; total revenue (including other income) was ₹643.9 Cr, +20.7% YoY. Consolidated PAT (net profit for the period, before minority interest) was ₹179.1 Cr, up 18.8% YoY and 3.6% QoQ, with basic EPS of ₹23.27 versus ₹20.10 a year ago. Neither the current nor the year-ago quarter carries any exceptional item, so this is a clean, comparable growth number. Management issued no formal quantitative guidance ahead of this print, so there is no company target to grade against; the closest available yardstick is broad analyst consensus (not quarter-specific) pegging FY27 PAT growth at 15-20% — the 18.8% YoY print sits within that band.
Q1 FY-2027 vs prior quarters
The operating story was actually stronger than the PAT growth alone suggests: EBITDA rose 23.0% YoY to ₹247.0 Cr with the EBITDA margin expanding to 38.4% from 37.7%, and PBT/EBIT margin rose to 35.0% from 34.6%. But gross margin slipped to 59.8% from 61.7% YoY as purchased/traded goods took a larger share of the cost mix, and the effective tax rate jumped to 20.5% (₹46.1 Cr tax on ₹225.2 Cr PBT) from 18.3% a year ago, compounded by a 32.8% YoY rise in depreciation as new capacity comes online. Net effect: consolidated PAT margin actually compressed to 27.8% from 28.3% YoY even as operating profitability improved — the quarter's real story is healthy operating leverage being partly offset below the line by tax and D&A, not a demand or pricing issue.
The stock went into the print at ₹2,590.85, down 2.5% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.
US revenue was the standout at ₹137 Cr (per the press release), +26% YoY, now roughly 22% of the geographic mix versus 78% for Emerging Markets; by segment, Rest-of-World PBT grew to ₹158.4 Cr (Q1FY26: ₹151.5 Cr) while the USA segment's PBT nearly tripled YoY to ₹33.3 Cr (from ₹9.9 Cr) — the regulated-market business is scaling faster than its still-smaller revenue base, backed by Caplin Steriles' 60 approved ANDAs (40+ more filing/in development) and CSU's own-label US business (33 launches to date, ~90% market-share retention on launched products). Alongside results, the board recommended a ₹4/share (200%) final dividend on top of the ₹4 interim already paid in June, taking total FY26 dividend to ₹8/share, and approved Dr. Sridhar Ganesan's MD reappointment (two more years from Aug 25, 2026) plus D. Muralidharan's elevation to Whole-Time Director while he retains the CFO role. Chairman C.C. Paarthipan's press-release commentary framed the quarter as delivering "healthy growth across both Emerging Markets and the US" with "disciplined execution" — the revenue and EBITDA numbers support that framing, though management's commentary does not address the tax-rate increase that capped net profit growth.
W1
Effective tax rate — jumped to 20.5% in Q1FY27 from 18.3% in Q1FY26; sustained elevation would keep capping PAT margin even as EBITDA grows
W2
Gross margin — slipped to 59.8% from 61.7% YoY on traded-goods mix; watch for recovery toward the ~60-62% historical band
W3
US launch cadence — management guided 12 more US product launches in FY27 (38 to date) and CSL's first Pre-Filled Syringe filing within FY27; watch delivery against these on the Q2 call
Clean typed statement, cross-verified against the company's own press release (Annexure 2) and earnings deck (Annexure 3) — all figures match exactly. No exceptional items in current or year-ago quarter. Standalone PAT is inflated by a lumpy ₹28.90 Cr dividend from wholly-owned subsidiary Caplin Point Far East (vs ₹8.12 Cr Q1FY26); consolidated eliminates this and is used as primary. Board also approved ₹4/share final dividend (total FY26 payout ₹8/share) and MD/WTD board changes.
Sterile Upside: US Momentum Meets Core Growth
Caplin Point enters Q1 FY-2027 on the back of two major US generic approvals—Foscarnet and Calcium Gluconate—offering potential uplift to margins while the core Indian business maintains its seasonal strength. The Street is watching execution: can the company sustain revenue growth and defend gross margins amid input cost volatility?
What to Expect
~₹350–370 Cr
Q1 seasonal strength (summer demand for injectables) + US base growth; prior year comp neutral
~52–54%
Input cost inflation vs pricing power; two USFDA approvals support product mix
~₹80–95 Cr
Operating leverage on higher revenue; fixed costs leverage expected
~15–17%
Assume tax rate ~20–22%; no exceptional items flagged
A strong quarter would mean: revenue >₹370 Cr with gross margins sustained >53%, signaling that the US sterile injectable base is growing faster than expected and pricing holds despite input costs. A weak print would show revenue <₹350 Cr or gross margins <51%, suggesting demand softness in India or margin compression from competition or FX.
On Track for FY-2027?
Caplin Point's track record is steady: FY-2026 saw core pharma and sterile injectables deliver mid-to-high single-digit growth. The company has guided for mid-teens revenue growth for FY-2027, anchored on two legs: (1) India domestic generics holding 10–12% growth, and (2) US steriles picking up pace as USFDA approvals convert to commercialization. Q1 FY-2027 should reflect that seasonal tailwind—if the US approvals (Foscarnet, Calcium Gluconate) ship volumes, this is the earliest data point. Watch for: guidance reaffirmation vs any cautious tone on execution or margin headwinds.
What the Street Says
Since Last Quarter: What Changed
1 · USFDA Approvals (May 2026)
Caplin Steriles received final USFDA approvals for Foscarnet Sodium Injection (6000 mg/250 mL infusion bag) and Calcium Gluconate Injection USP. Both are generic versions of established branded drugs, opening new addressable markets in the US IV injectables segment. No revenue yet in Q1, but validation of Caplin's sterile manufacturing platform is a strategic win.
2 · ₹4 Interim Dividend (May 2026)
Board approved ₹4.00 (200%) interim dividend for FY-2026, signaling confident cash generation and shareholder-friendly capital allocation. The payout rate (200% of face value) is generous and indicates management expects sustained profitability.
3 · Trading Window Closure (June 2026)
Standard insider trading blackout from July 1, 2026, ahead of Q1 results announcement. No unusual insider activity flagged; promoter holding stable at 70.57%.
4 · Valuation & Momentum (as of Aug 7)
Stock at ₹2577.15, near 52-week high (₹2700), up 71.5% off the 52-week low (₹1502.45). RSI 44.4 (neutral momentum); volume declining, suggesting some consolidation ahead of results. FII holdings at 5.75% (down 40 bps QoQ), DII steady at 2.49%. Technicals support near-term price support but not overbought.
The Setup
Caplin Point is in a transition quarter: the US sterile pipeline (Foscarnet, Calcium Gluconate) is now real, and Q1 FY-2027 is the first print to reflect early traction. India's generics and specialty business should deliver seasonal strength. The real question is execution: can margins hold as input costs press, and can the company guide for sustained mid-to-high teen growth for the full year? Watch three things on August 12: (1) US revenue contribution—even pre-commercial, do new approvals hint at near-term potential?; (2) Gross margin—is the company defending pricing or ceding share?; and (3) Full-year guidance—reaffirmed or trimmed?
Caplin Point enters Q1 FY-2027 with regulatory tailwinds (US sterile approvals) and seasonal momentum (India injections demand). Consensus expectations center on mid-to-high single-digit revenue growth with gross margins in the 52–54% band, anchored to full-year guidance of mid-teens growth. The Street's focus is narrow but real: validation of US sterile execution and margin defense in a rising input-cost environment. Results on August 12.